Abstract
Background and Aims: Insulin degrading enzyme (IDE) contributes to the degradation processes of insulin and Aβ. We aimed to investigate the role of IDE in type 2 diabetes patients with mild cognitive impairment (MCI).
Methods: A total of 146 individuals with type 2 diabetes were enrolled and divided into two groups according to the Montreal Cognitive Assessment (MoCA) score. Demographic characteristics, cognitive function and serum IDE level were examined.
Results: There were 75 patients with MCI and 71 patients without MCI. Diabetic patients with MCI had a higher serum level of IDE compared with the control group (p < 0.001). Among patients with MCI, serum IDE level was positively correlated with the MoCA score (r = 0.839; p < 0.001). Correlation analysis demonstrated that IDE was positively correlated with MoCA score (r = 0.815; p < 0.001) but negatively correlated with the Trail Making Test-B (r = −0.413; p < 0.001), fasting blood-glucose (r = −0.372; p < 0.001), glycosylated hemoglobin (r = −0.214; p = 0.015), homeostasis model of assessment for insulin resistance (r = −0.560; p < 0.001) and the mean amplitude of glycemic excursions (r = −0.551; p < 0.001) in all subjects. In logistic regression analysis for MCI, IDE (p = 0.010) was an independent variable, after adjusting for age, sex, education, liver function, kidney function, and lipid levels.
Conclusion: This study demonstrated a greater likelihood of MCI with decreasing serum IDE in patients with type 2 diabetes.
Keywords: Homeostasis model of assessment for insulin resistance, insulin degrading enzyme, mild cognitive impairment, the mean amplitude of glycemic excursions, the Trail Making Test-B, Type 2 diabetes.
Current Alzheimer Research
Title:Serum Insulin Degrading Enzyme Level and Other Factors in Type 2 Diabetic Patients with Mild Cognitive Impairment
Volume: 13 Issue: 12
Author(s): Jie Sun, Wenqing Xia, Rongrong Cai, Pin Wang, Rong Huang, Haixia Sun, Sai Tian, Xue Dong and Shaohua Wang
Affiliation:
Keywords: Homeostasis model of assessment for insulin resistance, insulin degrading enzyme, mild cognitive impairment, the mean amplitude of glycemic excursions, the Trail Making Test-B, Type 2 diabetes.
Abstract: Background and Aims: Insulin degrading enzyme (IDE) contributes to the degradation processes of insulin and Aβ. We aimed to investigate the role of IDE in type 2 diabetes patients with mild cognitive impairment (MCI).
Methods: A total of 146 individuals with type 2 diabetes were enrolled and divided into two groups according to the Montreal Cognitive Assessment (MoCA) score. Demographic characteristics, cognitive function and serum IDE level were examined.
Results: There were 75 patients with MCI and 71 patients without MCI. Diabetic patients with MCI had a higher serum level of IDE compared with the control group (p < 0.001). Among patients with MCI, serum IDE level was positively correlated with the MoCA score (r = 0.839; p < 0.001). Correlation analysis demonstrated that IDE was positively correlated with MoCA score (r = 0.815; p < 0.001) but negatively correlated with the Trail Making Test-B (r = −0.413; p < 0.001), fasting blood-glucose (r = −0.372; p < 0.001), glycosylated hemoglobin (r = −0.214; p = 0.015), homeostasis model of assessment for insulin resistance (r = −0.560; p < 0.001) and the mean amplitude of glycemic excursions (r = −0.551; p < 0.001) in all subjects. In logistic regression analysis for MCI, IDE (p = 0.010) was an independent variable, after adjusting for age, sex, education, liver function, kidney function, and lipid levels.
Conclusion: This study demonstrated a greater likelihood of MCI with decreasing serum IDE in patients with type 2 diabetes.
Export Options
About this article
Cite this article as:
Sun Jie, Xia Wenqing, Cai Rongrong, Wang Pin, Huang Rong, Sun Haixia, Tian Sai, Dong Xue and Wang Shaohua, Serum Insulin Degrading Enzyme Level and Other Factors in Type 2 Diabetic Patients with Mild Cognitive Impairment, Current Alzheimer Research 2016; 13 (12) . https://dx.doi.org/10.2174/1567205013666160615091043
DOI https://dx.doi.org/10.2174/1567205013666160615091043 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immune Responses to Adeno-Associated Virus Vectors
Current Gene Therapy Genetics of Bladder-Exstrophy-Epispadias Complex (BEEC): Systematic Elucidation of Mendelian and Multifactorial Phenotypes
Current Genomics Synthesis, Molecular Modeling and Biological Evaluation of 5-arylidene-N,N-diethylthiobarbiturates as Potential α-glucosidase Inhibitors
Medicinal Chemistry Functional Neuroimaging of Sleep Disorders
Current Pharmaceutical Design Applications of Artificial Neural Networks in Medical Science
Current Clinical Pharmacology Multifaceted Individualities in Pharmacological Treatments of Obesity
Current Clinical Pharmacology Preparation and Characterization of Rivastigmine Loaded Human Serum Albumin (HSA) Nanoparticles
Current Drug Delivery Current Progress of Reelin in Development, Inflammation and Tissue Remodeling: From Nervous to Visual Systems
Current Molecular Medicine Structure, Roles and Inhibitors of a Mitotic Protein Kinase Haspin
Current Medicinal Chemistry Aquaporins and Glia
Current Neuropharmacology Role of Cytokines in Neurological Disorders
Current Medicinal Chemistry Novel Kynurenic Acid Analogues in the Treatment of Migraine and Neurodegenerative Disorders: Preclinical Studies and Pharmaceutical Design
Current Pharmaceutical Design A Scientometrics Analysis and Visualization of Depressive Disorder
Current Neuropharmacology Mossy Fiber Sprouting as a Potential Therapeutic Target for Epilepsy
Current Neurovascular Research Co-Existence of GABA and Glu in the Hippocampal Granule Cells: Implications for Epilepsy
Current Topics in Medicinal Chemistry The Anticonvulsant Effects of Ketogenic Diet on Epileptic Seizures and Potential Mechanisms
Current Neuropharmacology Role of Resveratrol and its Analogues in the Treatment of Neurodegenerative Diseases: Focus on Recent Discoveries
CNS & Neurological Disorders - Drug Targets Treating Rapid Cycling Bipolar Disorder with Novel Medications
Current Psychiatry Reviews MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Chemical Composition and In Vitro Neuroprotective Activity of Fibre-Type Cannabis sativa L. (Hemp)
Current Bioactive Compounds